Edition:
India

Profile: Atara Biotherapeutics Inc (ATRA.OQ)

ATRA.OQ on NASDAQ Stock Exchange Global Select Market

22.07USD
1:30am IST
Change (% chg)

$0.22 (+1.01%)
Prev Close
$21.85
Open
$22.11
Day's High
$22.55
Day's Low
$21.83
Volume
338,043
Avg. Vol
161,696
52-wk High
$47.20
52-wk Low
$21.31

Atara Biotherapeutics, Inc., incorporated on August 22, 2012, is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. Cytotoxic T-cells, otherwise known as cytotoxic T lymphocytes (CTLs), can mount an immune response against an antigen or antigens in order to combat viral infection or disease.

The Company is investigating its T-cell product candidate, ATA129, which is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV), associated post-transplant lymphoproliferative disorder (EBV-PTLD). The Company focuses on designing two Phase III trials for ATA129 intended to support approval in two separate indications, the treatment of rituximab-refractory EBV-PTLD after hematopoietic cell transplant (HCT) and after solid organ transplant (SOT). The Company's T-cell product candidate, ATA188, is in development for the treatment of multiple sclerosis (MS). ATA188 is a third-party derived EBV-CTL that is targeted to specific antigens.

The Company's T-cell product candidate, ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company's T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV, an infection that occurs in some patients having received an HCT or SOT or are otherwise immunocompromised.

The Company competes with Cell Medica Ltd., Biogen Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., Merck KGaA, Sanofi Aventis, Genzyme Corporation, Novartis International AG, F. Hoffmann-La Roche Ltd, MedDay SA, AB Science, Amgen Inc., Celgene Corporation, Millennium Pharmaceuticals, Inc., Janssen Research & Development, LLC, Array Biopharma Inc., Karyopharm Therapeutics, Altor Bioscience Corporation, Morphosys AG, bluebird bio, Inc., Adaptimmune Therapeutics PLC, Actinium Pharmaceuticals Inc., Shire Plc, Merck & Co. Inc., Vical Inc., Helocyte, Inc., VBI Vaccines Inc., Hookipa Biotech and ViraCyte.

Company Address

Atara Biotherapeutics Inc

611 Gateway Blvd Ste 900
SOUTH SAN FRANCISCO   CA   94080-7015
P: +1650.2788930
F: +1302.5313150

Company Web Links